The lARC Monographs on the Evaluation of Carcinogenic Risks to Humans represent an international expert-consensus approach to carcinogen hazard identification. The long-term objective is to critically review and evaluate the published scientific evidence on carcinogenic hazards to which humans are exposed. These include chemicals, complex mixtures, physical agents, biological agents, occupational exposures, and lifestyle factors. National and international health agencies use the lARC Monographs as a source of scientific information and as the scientific basis for their actions to prevent exposure to known, probable, and possible carcinogens. Each lARC Monograph contains a critical review of the published scientific literature and an evaluation of the weight of the evidence that an agent can increase the risk of cancer. Agents are selected for evaluation based on evidence of human exposure and some evidence of carcinogenicity. Agents can be re-evaluated if significant new data become available. The program also collaborates on scientific workshops to determine how to make the best use of contemporary studies to identify agents that play a role in cancer development and to understand their mechanisms. The Preamble to each volume of lARC Monographs describes the principles and procedures that are followed, including the scientific criteria that guide the evaluations. Each lARC Monograph is developed by a Working Group of experts who conducted the original research, avoiding real or apparent conflicts of interests. Working Groups typically consist of 20-25 scientists from 8-12 countries, with expertise in cancer epidemiology, experimental carcinogenesis, and related disciplines. The Working Group meets to review and reach consensus on drafts prepared by the experts before the meeting, and to develop and reach consensus on the evaluations. Later, lARC scientists review the text and tables to ensure their scientific accuracy and clarity, and the volume is edited and published. Funds are requested to support two of the three volumes produced each year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA033193-33
Application #
8732603
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Program Officer
Johnson, Ronald L
Project Start
1985-09-01
Project End
2015-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
33
Fiscal Year
2014
Total Cost
$808,594
Indirect Cost
$112,131
Name
International Agency for Research on Cancer
Department
Type
DUNS #
279551881
City
Lyon
State
Country
France
Zip Code
69008
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2010) IARC monographs on the evaluation of carcinogenic risks to humans. Ingested nitrate and nitrite, and cyanobacterial peptide toxins. IARC Monogr Eval Carcinog Risks Hum 94:v-vii, 1-412
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2010) Household use of solid fuels and high-temperature frying. IARC Monogr Eval Carcinog Risks Hum 95:1-430
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2010) Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. IARC Monogr Eval Carcinog Risks Hum 92:1-853
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2008) IARC monographs on the evaluation of carcinogenic risks to humans. Volume 97. 1,3-butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide). IARC Monogr Eval Carcinog Risks Hum 97:3-471
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2002) Non-ionizing radiation, Part 1: static and extremely low-frequency (ELF) electric and magnetic fields. IARC Monogr Eval Carcinog Risks Hum 80:1-395
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2002) Man-made vitreous fibres. IARC Monogr Eval Carcinog Risks Hum 81:1-381
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2002) Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum 82:1-556
(1999) Oral contraceptives, combined. IARC Monogr Eval Carcinog Risks Hum 72:49-338
(1999) Hormonal contraceptives, progestogens only. IARC Monogr Eval Carcinog Risks Hum 72:339-97
(1999) Post-menopausal oestrogen-progestogen therapy. IARC Monogr Eval Carcinog Risks Hum 72:531-628

Showing the most recent 10 out of 65 publications